30.33
前日終値:
$29.10
開ける:
$29.23
24時間の取引高:
622.23K
Relative Volume:
0.46
時価総額:
$3.20B
収益:
-
当期純損益:
$-150.70M
株価収益率:
-19.57
EPS:
-1.55
ネットキャッシュフロー:
$-125.67M
1週間 パフォーマンス:
+4.69%
1か月 パフォーマンス:
+21.47%
6か月 パフォーマンス:
+138.53%
1年 パフォーマンス:
+14.69%
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Compare EWTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
EWTX
Edgewise Therapeutics Inc
|
30.25 | 3.08B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.49 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.93 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
827.19 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.39 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
349.33 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | 開始されました | Goldman | Neutral |
| 2025-07-30 | 開始されました | Raymond James | Strong Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-30 | 開始されました | Guggenheim | Buy |
| 2025-04-02 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-22 | 開始されました | Stifel | Hold |
| 2024-11-22 | 開始されました | Evercore ISI | Outperform |
| 2024-03-07 | 開始されました | Piper Sandler | Overweight |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2022-08-25 | ダウングレード | Goldman | Neutral → Sell |
| 2022-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-28 | 開始されました | Goldman | Neutral |
すべてを表示
Edgewise Therapeutics Inc (EWTX) 最新ニュース
Edgewise Therapeutics stock hits 52-week high at $30.26 By Investing.com - Investing.com India
Piper Sandler reiterates Overweight rating on Edgewise Therapeutics stock - Investing.com
Growth Recap: Can Edgewise Therapeutics Inc expand its profit margins2025 Earnings Impact & Weekly Stock Breakout Alerts - baoquankhu1.vn
Braveheart Bio names Marc Evanchik CSO - The Pharma Letter
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 - PR Newswire
Edgewise Therapeutics (EWTX): Analyst Consensus Reveals A 32% Upside Potential - DirectorsTalk Interviews
Dow Update: What analysts say about Edgewise Therapeutics Inc stockJuly 2025 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Short Interest Down 19.4% in January - MarketBeat
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
Y Intercept Hong Kong Ltd Invests $929,000 in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Responsive Playbooks and the EWTX Inflection - Stock Traders Daily
EPS Watch: Is Edgewise Therapeutics Inc exposed to currency risksRisk Management & Low Risk Growth Stock Ideas - baoquankhu1.vn
Returns Recap: Will Edgewise Therapeutics Inc benefit from current market trendsWeekly Risk Summary & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Edgewise Therapeutics Reports Q3 2025 Financial Results - MSN
Campbell & CO Investment Adviser LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX - MarketBeat
Edgewise Therapeutics director sells $3.39 million in shares By Investing.com - Investing.com India
Edgewise Therapeutics(EWTX.US) Director Sells US$3.4 Million in Common Stock - 富途牛牛
Retail Trends: Will Edgewise Therapeutics Inc stock hit new highs in YEAR2025 Market WrapUp & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Wall Street Zen Upgrades Edgewise Therapeutics (NASDAQ:EWTX) to "Hold" - MarketBeat
Insider Sell: Badreddin Edris Sells 115,471 Shares of Edgewise Therapeutics Inc (EWTX) - GuruFocus
Edgewise Therapeutics (NASDAQ:EWTX) Director Sells $3,399,466.24 in Stock - MarketBeat
Edgewise Therapeutics director sells $3.39 million in shares - Investing.com
Retail Trends: Is Edgewise Therapeutics Inc trading at a discountJuly 2025 Institutional & Real-Time Volume Triggers - baoquankhu1.vn
Understanding the Setup: (EWTX) and Scalable Risk - Stock Traders Daily
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A 39% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Edgewise Therapeutics, Inc. (EWTX) outlines priorities for 2026 - MSN
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy? - Sahm
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 6.4%Time to Sell? - MarketBeat
Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 - Insider Monkey
14 Best Booming Stocks to Buy Right Now - Insider Monkey
A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed 2026 Clinical Milestone Update - Sahm
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX - TechStock²
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 7%Should You Buy? - MarketBeat
Technical Analysis: Is Edgewise Therapeutics Inc subject to activist investor interest2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Edgewise Therapeutics (EWTX) Is Up 8.8% After Mapping Its 2026 Rare-Disease Pipeline Priorities – And What's Next - Yahoo Finance
A Look At Edgewise Therapeutics (EWTX) Valuation After J P Morgan Clinical Pipeline Update - Yahoo Finance
Edgewise Therapeutics (EWTX) Stock Analysis: A 58% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 - Sahm
Edgewise Therapeutics provides corporate updates and highlights priorities for 2026 - marketscreener.com
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Sectors Review: What analysts say about Edgewise Therapeutics Inc stock - baoquankhu1.vn
Why Edgewise Therapeutics Inc stock could benefit from AI revolutionPortfolio Update Report & Safe Entry Zone Tips - Bộ Nội Vụ
Can Edgewise Therapeutics Inc. stock double in next 5 yearsJuly 2025 Highlights & Daily Price Action Insights - ulpravda.ru
Can Edgewise Therapeutics Inc. stock continue upward trendWatch List & Low Risk Profit Maximizing Plans - ulpravda.ru
Momentum Shift: Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - Улправда
Is Edgewise Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Macro Moves & Growth Oriented Trade Recommendations - Улправда
Edgewise Therapeutics rises 15.5% - MSN
Will Sure Ventures Plc (08F) stock extend growth storyRate Cut & Intraday High Probability Alerts - ulpravda.ru
Is Edgewise Therapeutics Inc. stock affected by interest rate hikesEarnings Performance Report & Free Verified High Yield Trade Plans - ulpravda.ru
Edgewise Therapeutics Inc (EWTX) 財務データ
収益
当期純利益
現金流量
EPS
Edgewise Therapeutics Inc (EWTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Edris Badreddin | Director |
Jan 21 '26 |
Sale |
29.44 |
115,471 |
3,399,466 |
19,820 |
大文字化:
|
ボリューム (24 時間):